Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rostam Osanlou

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
BMJ Open|July 5, 2022
Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissionsRostam Osanlou, Lauren Walker, Dyfrig A Hughes, et al.
British Journal of Clinical Pharmacology|October 20, 2020
Warfarin dosing algorithms: A systematic reviewInnocent G Asiimwe, Eunice J Zhang, Rostam Osanlou, et al.
Clinical Pharmacology and Therapeutics|December 24, 2019
Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-AnalysisInnocent G Asiimwe, Eunice J Zhang, Rostam Osanlou, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
The Journal of Infection|April 13, 2023
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]Xinxue Liu, Alasdair Ps Munro, Shuo Feng, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
BMJ Open|July 5, 2022
Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissionsRostam Osanlou, Lauren Walker, Dyfrig A Hughes, et al.
British Journal of Clinical Pharmacology|October 20, 2020
Warfarin dosing algorithms: A systematic reviewInnocent G Asiimwe, Eunice J Zhang, Rostam Osanlou, et al.
Clinical Pharmacology and Therapeutics|December 24, 2019
Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-AnalysisInnocent G Asiimwe, Eunice J Zhang, Rostam Osanlou, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
The Journal of Infection|April 13, 2023
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]Xinxue Liu, Alasdair Ps Munro, Shuo Feng, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Pageof 1